Login to Your Account



Memories of Ionsys?

NuPathe Tumbles After CRL Delays Migraine Patch Zelrix

By Jennifer Boggs


Wednesday, August 31, 2011
NuPathe Inc.'s Zelrix, a version of sumatriptan delivered via a patch for migraine sufferers unable to take the oral therapy, won't hit the market next year as planned after the FDA issued a complete response letter (CRL) requesting additional information, news that sent shares of the Conshohocken, Pa.-based firm plunging 34.6 percent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription